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In Response: Alanio et al. comment that the preva-
lence of azole-resistant Aspergillus disease may differ, 
depending on location of the hospital where patients are 
admitted and the patients’ underlying disease (1). Deter-
mining local or regional epidemiology, especially in areas 
where azole-resistant isolates are found in the environment, 
is indeed important. These isolates commonly harbor the 
TR
34
/L98H or TR
46
/Y121F/T289A resistance mechanism. 
Patients may inhale azole-resistant spores in the air and 
subsequently develop azole-resistant disease, even when 
they have never been treated with azoles (2). Although 
risk for inhalation of azole-resistant Aspergillus spores 
arguably might be similar for all patients, surveillance of 
Aspergillus isolates in the Netherlands indicates that resis-
tance rates vary among hospitals. When all A. fumigatus 
isolates cultured from patients were investigated for azole 
resistance, resistance rates in the Netherlands ranged from 
4.3% to 19.2% in 2013 and 3.8% to 13.3% in 2014 (3). The 
highest and lowest resistance rates were found in hospi-
tals only 39 km from each other, supporting the observa-
tion made by Alanio et al. about variations in prevalence of 
azole-resistant Aspergillus disease (1).
More detailed surveillance is required to determine if 
local treatment guidelines should be reassessed. Two recent 
studies in the Netherlands investigated the risk of azole-
resistant invasive aspergillosis in high-risk populations. 
One study conducted in a 33-bed tertiary-care university 
hospital intensive-care unit (ICU) showed that 26% of cul-
ture-positive patients with presumed invasive aspergillosis 
harbored azole-resistant isolates, a proportion 14% higher 
than that found in other departments in the hospital (p = 
0.06) (4). The second study, which investigated azole re-
sistance in the primary routine culture (including respira-
tory cultures) of 105 ICU and hematology patients, showed 
that the resistance rate (24.6%) for hematology patients 
was higher than the rate (4.5%) for ICU patients (5). Other 
countries have also reported higher prevalence of resis-
tance in high-risk populations than in other populations. 
One problem with assessing prevalence of azole resis-
tance is that the recovery of A. fumigatus in culture may 
vary considerably among different patient groups. A recent 
audit in our hematology department over the past 5 years 
indicated that A. fumigatus was cultured in only 35% of 
patients who underwent bronchoalveolar lavage as part of a 
diagnostic work-up for pulmonary infection (P.E. Verweij, 
unpub. data). This outcome indicates that in culture-nega-
tive patients, presence of azole resistance will be missed.
In agreement with Alanio et al. (1), recent studies 
show a need to determine frequency of azole resistance 
at the hospital level and within different patient groups or 
departments. Although surveillance of unselected clinical 
cultures provides resistance rates at a national level and 
offers information about the epidemiology of resistance 
mechanisms, regular audits in specific patient popula-
tions are warranted to determine the frequency of azole 
resistance among different risk groups. These audits will 
enable clinicians to determine whether reassessment of 
azole monotherapy as a primary treatment option is neces-
sary. Given the low and variable rates of positive cultures, 
culture-negative patients should also be included in azole-
resistance surveillance programs. 
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To the Editor: As members of the French Ministry 
of Health Working Group on autochthonous urinary schis-
tosomiasis, we read with interest the 2 recently published 
articles regarding schistosomiasis screening of travelers to 
Corsica, France (1,2). Surprisingly, the authors of both ar-
ticles lacked evidence to support the diagnosis of schistoso-
miasis in most of what they referred to as confirmed cases. 
The diagnostic standard for confirmation of urinary schis-
tosomiasis is identification of eggs by microscopic exami-
nation of urine samples (3–5). If this criterion were applied 
in both reports, only 1 patient of the 7 allegedly confirmed 
cases would actually be confirmed.
The low sensitivity of microscopy is well known. 
Therefore, different serologic tests have been developed, 
including Western blot (WB). In the study based on travel-
ers from Italy (1), the SCHISTO II WB IgG test (LDBIO 
Diagnostics, Lyon, France) was used. This test, available 
since 2015, is based on both Schistosoma haematobium and 
S. mansoni antigens and has not been evaluated by anyone 
other than the manufacturer. Moreover, the authors did not 
report any details regarding the molecular weight and num-
ber of specific bands observed on the strip.
In the study by authors from the GeoSentinel Surveil-
lance Network (2), both cases that could have been infected 
after 2013, since exposure occurred only in 2014, and 4 
cases which reported bathing in rivers in Corsica other than 
the Cavu River had just 1 weakly positive serologic screen-
ing test. Hence, irrespective of the criteria for a confirmed 
case of schistosomiasis described above, it appears difficult 
to conclude that confirmation could rely on only 1 positive 
serologic test, even a WB.
Altogether, these 2 studies identified only 1 patient with 
parasitological evidence of infection that was attributable to 
the already known 2013 focus in Cavu River. Therefore, these 
articles do not provide evidence of transmission of schistoso-
miasis in Corsica after 2013 or outside the Cavu River.
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